Guardant Health, Inc. (GH) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Guardant Health, Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: A leading precision oncology company providing blood and tissue tests for cancer screening, monitoring, and therapy selection. Key products include Guardant360 (therapy selection), Guardant Reveal (minimal residual disease), and Shield (early colorectal cancer screening).
Key Milestone: In July 2024, the company received FDA approval for its Shield blood test for colorectal cancer screening, becoming the first blood test approved by the FDA for primary colorectal cancer screening and meeting Medicare coverage requirements.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $739.0 million | $563.9 million | +31% |
| Precision Oncology Testing Revenue | $687.9 million | $514.2 million | +34% |
| Net Loss | $(436.4) million | $(479.4) million | -9% (Improvement) |
| Operating Loss | $(443.6) million | $(564.7) million | -21% (Improvement) |
| Cash, Cash Equivalents & Marketable Securities | $944.2 million | $1.17 billion (approx.) | Decrease |
| Convertible Senior Notes (Principal) | $1.15 billion | $1.15 billion | 0% |
| Stock-Based Compensation | $140.4 million | $90.8 million | +55% |
Note: The filing does not provide a specific "Gross Margin" percentage, but Cost of Revenue was $289.8 million in 2024 vs $227.1 million in 2023.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 34% increase in clinical testing volume (approx. 206,700 tests in 2024 vs 172,900 in 2023) and increased reimbursement rates, particularly for the Guardant360 LDT test under Medicare (increased to $5,000 effective Jan 1, 2024).
- Expense Fluctuations:
- R&D: Decreased 5% to $347.8 million, primarily due to reduced costs for the ECLIPSE clinical study as it neared completion.
- Sales & Marketing: Increased 24% to $364.9 million due to commercial team expansion and marketing for the Shield launch.
- Other Operating Expense: Decreased significantly from $83.4 million in 2023 to $0 in 2024. The 2023 charge was a legal accrual related to a jury verdict in the TwinStrand Biosciences patent infringement case.
- Investment Losses: "Other income (expense), net" swung from a $53.2 million gain in 2023 to a $42.6 million loss in 2024, primarily due to $44.4 million in unrealized/realized losses on the sale of marketable equity securities (Lunit, Inc.).
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects to incur additional operating losses in the near future as they invest in clinical studies, new product development, and sales expansion. They believe current cash resources are sufficient for more than 12 months.
- Legal Contingencies:
- TwinStrand Biosciences: A jury verdict in Nov 2023 awarded TwinStrand $83.4 million. Guardant recorded this liability in 2023 and is vigorously contesting the verdict via post-trial motions and potential appeal. $103.6 million of restricted cash is held as collateral for this dispute.
- Natera: In Nov 2024, a jury awarded Guardant $292.5 million in a false advertising case against Natera. Post-trial motions are pending.
- False Claims Act: The company is cooperating with a civil investigative demand regarding billing for Guardant360 tests.
- Regulatory Risks: Significant risk regarding the FDA's finalized rule requiring Laboratory Developed Tests (LDTs) to undergo premarket review, with implementation expected in Spring 2025 (subject to litigation). Changes in Medicare reimbursement policies (PAMA) also pose risks to revenue stability.
- Debt: In February 2025 (subsequent event), Guardant issued $600 million of new 1.25% convertible notes due 2031 to retire approximately $659.3 million of its 2027 notes.
Key Facts for Investor Verification
- Profitability Path: Verify the timeline and cost assumptions for achieving profitability, given the $2.6 billion accumulated deficit and continued net losses.
- Reimbursement Stability: Monitor the impact of the new FDA LDT rule and potential changes in Medicare reimbursement rates (PAMA) on the variable consideration estimates used for revenue recognition.
- Legal Resolution: Track the status of the TwinStrand appeal and the Natera post-trial motions, as these involve significant cash collateral and potential windfalls/liabilities.
- Shield Commercialization: Assess the actual uptake and reimbursement rates for the newly FDA-approved Shield test in the colorectal screening market.
- Debt Structure: Review the terms of the new 2031 convertible notes issued in February 2025 and the remaining balance of the 2027 notes.